<DOC>
	<DOCNO>NCT00890253</DOCNO>
	<brief_summary>A prospective , non-randomized two stage monocentric phase II clinical trial evaluate de-novo calcineurin-inhibitor ( CNI ) -free immunosuppressive regimen base induction therapy anti-CD25 monoclonal anti-body ( basiliximab ) , mycophenolic acid ( MPA ) , mammalian target rapamycin ( mTOR ) - inhibition everolimus determine safety investigate preliminary efficacy patient impaired renal function time-point liver transplantation ( OLT ) regard incidence steroid resistant acute rejection within first 30 day liver transplantation .</brief_summary>
	<brief_title>Safety Study Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Patients undergo primary liver transplantation . 2 . Patients older 18 year . 3 . Patients hepatorenal syndrome . 4 . Female patient childbearing potential willing perform highly effective contraception study 12 week conclusion study participation . 5. eGFR &lt; 50 ml/min time point transplantation . 6 . Serum creatinine level &gt; 1.5 mg/dL timepoint transplantation . 1 . Patients pretransplant renal replacement therapy &gt; 14 day . 2 . Patients reason renal impairment hepatorenal syndrome . 3 . Patients know hypersensitivity mTORinhibitors . 4 . Patients know hypersensitivity mycophenolate acid . 5 . Patients know hypersensitivity anti CD 25monoclonal antibody . 6 . Patients platelets &lt; 50.000/nl prior initiation therapy mTOR inhibition . 7 . Patients triglyceride &gt; 350 mg/dl cholesterol &gt; 300 mg/dl refractory optimal medical treatment prior initiation therapy mTOR inhibition . 8 . Severe systemic infection woundhealing disturbance . 9 . Multiple organ graft recipient . 10 . Patients sign hepatic artery stenosis directly prior initiation therapy everolimus . 11 . Pregnant woman include study . 12 . Patients psychological , familial , sociologic geographic condition potentially hamper compliance study protocol followup schedule . 13 . Patients guardianship ( e.g. , individual able freely give informed consent ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Renal impairment</keyword>
	<keyword>Liver transplantation</keyword>
	<keyword>Chronic Renal Insufficiency</keyword>
</DOC>